drugset / Trial / NCT05315713
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab, with or without atezolizumab, in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who have received at least two previous lines of systemic therapy.
Timeline
- Start
- 2022-05-10
- Primary completion
- 2023-07-19
- Completion
- 2023-07-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Mosunetuzumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Tiragolumab | Monoclonal antibody | — | Intravenous |